News: Two Small-Cap Stocks Head and Shoulders Above Peers with New Drug Delivery Systems Media Inc.

Companies Mentioned:

Primary Exchange: OTC:BB
Under the Symbol: CWNM



0.00% News: Two Small-Cap Stocks Head and Shoulders Above Peers with New Drug Delivery Systems

Tuesday, February 12, 2013 4:55 PM

MISSISSAUGA, Ontario, February 12, 2013 -- Media, Inc. ( announces its latest article titled “Two Small-Cap Stocks Head and Shoulders Above Peers with New Drug Delivery Systems.”

Companies mentioned in this article include Crown Marketing Pharmaceuticals (OTCQB:CWNM), Eli Lilly & Co. (NYSE:LLY), Biogen Idec Inc. (Nasdaq:BIIB), Sanofi SA (NYSE:SNY), Unilife Corporation (Nasdaq:UNIS), Retractable Technologies Inc. (AMEX:RVP) and Antares Pharmaceutical, Inc. (Nasdaq:ATRS).

Article Excerpt:

The pharmaceutical business is starving for new therapies and technologies to shepherd in the next wave of treatments to combat diseases. Subsequently, large pharmaceutical companies are dolling-out increasing amounts of money to try and get an edge on competitors as they slowly fall one by one off the so-called patent cliff, costing them billions of dollars annually as blockbuster drugs lose protection from generics.

Make no mistakes about it; the cliff is steep and expensive. Of the $860 billion in global sales of pharmaceuticals in 2010, 133 drugs accounted for about 34 percent, or nearly $300 billion, of total sales. 13 of those drugs, or 9.8 percent, face patent expiration in the next five years. In 2013 alone, EvaluatePharma estimates drugs generating $29 billion annually will lose patent protection. Included in this group are Eli Lilly & Co.’s (NYSE:LLY) antidepressant Cymbalta and diabetes drug Humalog, Biogen Idec Inc.’s (Nasdaq:BIIB) multiple sclerosis drug Avonex (although Biogen contests that it has extended the patent) and Purdue Pharma’s chronic pain drug OxyContin.

Taking the hit in 2012 were drugs such as Sanofi SA’s (NYSE:SNY) blockbuster blood thinner Plavix and Pfizer Inc.’s (NYSE:PFE) cholesterol drug Lipitor, which accounted for almost 16 percent of Pfizer’s total drug sales in 2010.

As the competition continues to stiffen in drug development, another pathway to prosperity that is catching the attention of the investment community is through improvements in drug delivery systems, or the means to get therapeutics into the body. These new technologies address fundamental challenges of pharmaceutical companies not only in developing novel therapeutics, but also potentially extending intellectual property rights on existing drugs.

The full version of this article can be found at:  

About is focused on the small-cap / penny stock market and has become a reputable name in the investment community. runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. runs a daily technical penny stocks to watch feature, has daily market write-ups, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more for the average investor. also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria looks for includes strong revenues, a seasoned management, innovative business plans, among many others. also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here:

Contact: Media, Inc.

Peter Szafranski -- President

Phone: (905) 361-5680

E-Mail: [email protected]

Websites: /


Note: has been compensated three thousand two hundred fifty dollars by a third-party, OTC Stock Review for its efforts in presenting this CWNM report on its web site and distributing it to its database of subscribers as well as other services. For a complete disclaimer, investors are encouraged to click here: